

Supplementary Table 1: All studies included in the systematic review.

Author (year)	Pain data reported in study	Risk of bias (score on NOS)
Delgado (2022) ¹	Patients with FMD reporting pain = 64/100 (64%)	Moderate (4)
Forejtova (2022) ²	Median PainDETECT (152 patients with mFND) = ~6/10 (IQR = ~4–8)	Low (8)
Gandolfi (2022) ³	Patients with FMD reporting pain = 44/64 (69%) Mean BPI in telemedicine group (32 patients with FMD): Before 5-day programme = 20.69/40 (SD = 14.8) intensity; 31.13/70 (SD = 24.21) interference After 12-week telemedicine programme = 15.44/40 (SD = 13.30) intensity; 20.84/70 (SD = 20.76) interference Mean BPI in self-management group (32 patients with FMD): Before 5-day programme = 17.91/40 (SD = 12.04) intensity; 27.47/70 (SD = 24.82) interference After 12-week self-management programme = 18.63/40 (SD = 13.11) intensity; 27.88/70 (SD = 24.57) interference	Moderate (6)
Geroin (2022) ⁴	Patients with FMD reporting pain = 72/100 (72%)	Low (7)
Gorenflo (2022) ⁵	Chronic pain was more common in female patients with PNES than female patients with epilepsy (odds ratio = 2.96; 95% CI = 1.20–7.34) Fibromyalgia was more common in patients with PNES than patients with epilepsy (odds ratio = 3.66; 95% CI = 1.10–12.25)	Low (7)
Massot-Tarrus (2022) ⁶	Patients with FS reporting pain = 33/194 (17%) Patients with FS and epilepsy reporting pain = 6/47 (13%)	Low (7)
Mostile (2022) ⁷	Patients with FMD reporting pain = 104/188 (55%)	Low (7)
Sandri (2022) ⁸	Patients with FMD reporting moderate or severe pain = 18/60 (30%) Mean pain score = 2.81/5 (SD = 1.37)	Moderate (5)
Teodoro (2022) ⁹	Median PainDETECT (19 patients with FCD) = 6/38 (IQR = 2–11) Median PainDETECT (23 healthy controls) = 1/38 (IQR = 0–5)	Moderate (6)
Gandolfi (2021) ¹⁰	Patients with FMD reporting pain = 26/33 (79%) Mean BPI in rehabilitation programme (33 patients with FMD): On admission = 19.21/40 (SD = 11.92) intensity; 33.58/70 (SD = 24.89) interference At 5-day discharge = 17.61/40 (SD = 11.89) intensity; 27.70/70 (SD = 24.16) interference At 3-month follow-up = 20.15/40 (SD = 12.01) intensity; 33.61/70 (SD = 23.16) interference	Low (7)
Gray (2021) ¹¹	Patients with FD referred to orthopaedic surgery reporting pain = 29/29 (100%) Patients receiving physiotherapy without improvement in pain = 22/29 (76%) Patients with worsening pain following surgery = 6/12 (50%)	High (2)

Author (year)	Pain data reported in study	Risk of bias (score on NOS)
Katyal (2021) ¹²	Patients with FS reporting pain = 72/149 (48%) Patients with epilepsy reporting pain = 38/230 (17%)	Low (8)
Lagrand (2021) ¹³	Patients with FMD reporting pain = 197/320 (62%) Patients with other hyperkinetic movement disorders reporting pain = 150/554 (27%)	Low (7)
Tinazzi (2021) ¹⁴	Patients with different forms of FMD reporting pain: FD = 18/38 (47%); FW = 22/58 (38%); FGD = 5/17 (29%); FJ = 5/23 (22%); FT = 7/40 (18%)	Moderate (5)
Stephen (2021) ¹⁵	Patients with FD reporting pain = 65/85 (76%) Patients with other dystonias reporting pain = 24/80 (30%) Opiate/opioid use in patients with FD = 25/85 (29%)	Low (7)
Aybek (2020) ¹⁶	Patients with FMD reporting pain: UK = 79/100 (79%); Canada = 50/90 (56%)	Moderate (4)
Gelauff (2020) ¹⁷	Patients with FMD reporting pain = 46/179 (26%) Median SF-36 (lower = worse) pain = 46/100 (IQR = 22–80)	Moderate (6)
Linden (2020) ¹⁸	Patients with FND reporting pain during WW1: Soldiers = 91/436 (21%); male civilians = 47/153 (31%); female civilians = 156/321 (49%)	Moderate (6)
O'Connell (2020) ¹⁹	Patients with mFND reporting pain = 46/98 (47%)	Low (7)
Stone (2020) ²⁰	Patients with FW reporting chronic back pain = 43/107 (40%)	Moderate (6)
Tinazzi (2020) ²¹	Patients with FMD reporting pain: 172/410 (42%)	Low (8)
Tomic (2020) ²²	Patients with FND reporting pain: Affected body part = 67/100 (67%); unaffected body part = 50/100 (50%)	Low (8)
Van der Feltz-Cornelis (2020) ²³	Patients with FND reporting pain = 54/62 (87%) Patients with BPI ≥ 3 ("pain of clinical significance") = 52/62 (84%) Patients with pain medication use (except opiates) = 24/64 (38%); opiates = 12/64 (19%) Mean BPI in psychotherapy group (38 patients with FND): Baseline = 5.68/10 (SD = 2.60) Post-intervention = 5.58/10 (SD = 2.51)	Moderate (6)

Author (year)	Pain data reported in study	Risk of bias (score on NOS)
Gelauff (2019) ²⁴	Median SF-36 (lower = worse) pain (107 patients with FMD): Baseline = 33/100 (IQR = 35) Follow-up (mean 14 years) = 20/100 (IQR = 20) Median SF-36 (lower = worse) pain (neurological controls): Baseline (38 patients) = 50/100 (IQR = 24) Follow-up (23 patients) = 20/100 (IQR = 20)	Low (8)
Hanzlikova (2019) ²⁵	Mean pain scores (22 patients with FMD): Current = 5.0/10 (SD = 2.9); average = 6.3/10 (SD = 2.4); maximal = 7.6/10 (SD = 2.4) Mean pain scores (22 healthy controls): Current = 0.1/10 (SD = 0.3); average = 1.9/10 (SD = 2.0); maximal = 1.0/10 (SD = 1.1)	Low (7)
Jennum (2019) ²⁶	Rheumatism-related pain in patients with FS: In 3 years pre-diagnosis = 19/455 (4%) In 3 years post-diagnosis = 26/472 (6%)	Low (8)
Jimenez (2019) ²⁷	Patients with FND reporting pain: Back = 26/49 (53%); neck = 15/49 (31%); joint = 9/49 (19%); neuropathic = 8/49 (16%); myofascial = 6/49 (12%); abdominal = 6/49 (12%) Mean PDI in multidisciplinary pain programme (49 patients with FND): Pre-intervention = 46.4/70 Post-intervention = 20.9/70	Moderate (4)
Serranova (2019) ²⁸	Patients with FMD reporting lower limb pain = 56/90 (62%) Mean VAS pain in past 4 weeks = 5.6/10 (SD = 3) Healthy controls reporting lower limb pain = 9/76 (12%)	Low (7)
Gelauff (2018) ²⁹	Median SF-36 (lower = worse) pain (181 patients with FMD) = 46/100 (IQR = 57)	Moderate (5)
Glass (2018) ³⁰	Chronic pain disorder in patients with motor FND = 22/100 (22%) Fibromyalgia in patients with motor FND = 10/100 (10%)	Low (8)
Morgante (2018) ³¹	Mean pain scores (12 patients with FD): Severity = 4.8/10 (SD = 2.0); duration = 3 years (SD = 1.3); disability = 2.3/5 (SD = 0.9) Mean pain scores (10 patients with idiopathic cervical dystonia): Severity = 7.2/10 (SD = 3.3); duration = 3.9 years (SD = 2.9 years); disability = 2.6/5 (SD = 1.6)	Low (7)
Petrovic (2018) ³²	Patients with FD reporting pain = 34/48 (71%)	Moderate (6)

Author (year)	Pain data reported in study	Risk of bias (score on NOS)
Vechetova (2018) ³³	Mean pain scores (61 patients with FMD): Current = 4.2/10 (SD = 3); average = 5.5/10 (SD = 3); maximal = 6.9/10 (SD = 3) Mean pain scores (61 healthy controls): Current = 0.9/10 (SD = 1); average = 1.4/10 (SD = 2); maximal = 2.7/10 (SD = 3)	Low (8)
Erba (2017) ³⁴	Patients with FS reporting pain after seizure = 10/17 (59%) Patients with epilepsy reporting pain after seizure = 1/11 (9%)	Moderate (6)
Kerr (2017) ³⁵	Patients with FS reporting pain = 30/332 (9%) Patients with FS and epilepsy reporting pain = 7/53 (13%) Patients with epilepsy reporting pain = 25/750 (3%)	Low (8)
Matin (2017) ³⁶	Patients with FMD reporting pain = 22/100 (22%)	Low (8)
Nielsen (2017) ³⁷	Patients with FMS reporting slight-to-moderate pain = 24/60 (40%); severe-to-extreme = 28/60 (47%) Mean SF-36 bodily pain in intervention group (30 patients with FMS): Baseline = 45.6/100 (SD = 33.5) At 6 months = 47.4/100 (SD = 33.1) Mean SF-36 bodily pain in control group (30 patients with FMS): Baseline = 32.1/100 (SD = 25.3) At 6 months = 33.9/100 (SD = 27.4)	Low (8)
Pleizier (2017) ³⁸	Patients with FNS reporting pain = 154/195 (79%) Baseline pain scores (195 patients with FNS): Mean SF-36 (lower = worse) pain = 42.6/100 (SD = 29.0); mean VAS pain = 48.6/100 (SD = 25.1); mean PCS = 18.1/52 (SD = 13.2) Pain scores at 12 months in immediate GP management group (100 patients with FNS): Mean VAS pain = 42.22/100 (SD = 26.56); mean PCS = 13.61/52 (SD = 12.86); mean SF-36 bodily pain = 50.14/100 (SD = 25.40) Pain scores at 12 months in initial neurologist management group (95 patients with FNS): Mean VAS pain 48.17/100 (SD = 25.98); mean PCS = 14.81/52 (SD = 12.51); mean SF-36 bodily pain = 49.55/100 (SD = 27.64)	Low (8)
Zutt (2017) ³⁹	Median SF-36 (lower = worse) pain (16 patients with FJ) = 49/100 (IQR = 52) Median SF-36 (lower = worse) pain (23 patients with cortical myoclonus) = 80/100 (IQR = 33)	Moderate (6)
Perez (2016) ⁴⁰	Chronic pain syndrome in patients with FNS = 15/49 (31%) Fibromyalgia in patients with FNS = 4/49 (8%)	Low (8)

Author (year)	Pain data reported in study	Risk of bias (score on NOS)
Salinsky (2016) ⁴¹	Mean number of emergency department presentations due to pain in 3 years pre-diagnosis: Patients with PNES (n = 28) = 2.50 Patients with epilepsy (n = 31) = 0.65 Mean number of emergency department presentations due to pain in 3 years post-diagnosis: Patients with PNES (n = 28) = 2.39 Patients with epilepsy (n = 31) = 0.42	Moderate (6)
Elliott (2014) ⁴²	Patients with FS reporting pain = 117/324 (36%) Patients with FS and epilepsy reporting pain = 23/84 (27%) Patients with epilepsy reporting pain = 35/281 (13%)	Low (8)
Parees (2014) ⁴³	Patients with FMD reporting pain before the onset of functional motor symptoms = 4/50 (8%)	Moderate (6)
Thomas (2013) ⁴⁴	Patients with FS reporting pain = 60/86 (70%)	Moderate (4)
Gazzola (2012) ⁴⁵	Patients with FS reporting pain = 40/85 (47%) Patients with idiopathic generalised epilepsy reporting pain = 10/85 (12%) Prescription pain medication use in patients with FS = 20/85 (24%); opiates = 12/85 (14%)	Moderate (6)
Driver-Dunckley (2011) ⁴⁶	Chronic pain in patients with PNES = 78/116 (67%) Chronic pain in patients with psychogenic movement disorders = 42/56 (75%)	Moderate (6)
Stone (2010) ⁴⁷	Patients with FW reporting pain: Other than affected limb = 68/107 (64%); back = 39/107 (36%); affected limb = 35/107 (33%); muscle = 30/107 (28%); joint = 29/107 (27%); neck = 20/107 (19%) Median SF-36 (lower = worse) pain = 33/100 (IQR = 22-44) Patients with other neurological weakness reporting pain: Other than affected limb = 16/46 (35%); back = 8/46 (17%); affected limb = 9/46 (20%); muscle = 6/46 (13%); joint = 4/46 (9%); neck = 1/46 (2%)	Moderate (6)
Ibrahim (2009) ⁴⁸	Patients with FD reporting pain = 3/35 (9%)	Moderate (5)
Kuyk (2008) ⁴⁹	Mean SF-36 (lower = worse) pain (22 patients with FS) = 58.5/100	Moderate (6)
Hantke (2007) ⁵⁰	Analgesic use in patients with FS = 79/170 (47%); "narcotic analgesics" = 55/170 (32%)	Low (8)
Reuber (2007) ⁵¹	Patients with FNS reporting pain = ~19/91 (>20%) Mean SF-36 bodily pain in psychotherapy group (63 patients with FNS): Baseline = 5.9/11 (SD = 2.7) Post-intervention = 6.0/11 (SD = 2.8)	Moderate (6)

Author (year)	Pain data reported in study	Risk of bias (score on NOS)
Dworetzky (2005) ⁵²	Patients with FD reporting pain = 19/22 (86%) Patients with epilepsy reporting pain = 13/26 (50%)	Moderate (6)
Schrag (2004) ⁵³	Patients with FD reporting pain = 38/41 (93%)	Moderate (5)
Stone (2004) ⁵⁴	Patients with FMS reporting pain = 15/30 (50%) Patients with FS reporting pain = 6/20 (30%)	Moderate (6)
Fishbain (2003) ⁵⁵	Non-dermatomal sensory abnormalities in patients with chronic pain = 74/283 (26%)	Low (7)
Birket-Smith (2002) ⁵⁶	Patients with FND reporting pain = 37/38 (97%)	Moderate (6)
Ettinger (1999) ⁵⁷	Patients with FS reporting pain = 43/56 (77%)	Moderate (4)
Barry (1998) ⁵⁸	Patients with FS reporting pain = 11/37 (30%)	Moderate (5)
Dula (1995) ⁵⁹	Patients with conversion disorder presenting to the emergency department due to pain = 5/42 (12%)	High (3)
Fishbain (1991) ⁶⁰	Non-dermatomal sensory abnormalities in patients with chronic pain = 100/247 (40%)	Low (9)
Lempert (1990) ⁶¹	Patients with FS reporting pain = 8/50 (16%)	Moderate (6)
Weintraub (1988) ⁶²	FND in patients with chronic pain syndrome = 15/35 (43%)	Moderate (4)
Fishbain (1986) ⁶³	Conversion disorder in patients with chronic pain = 108/283 (38%)	Low (7)
Reich (1983) ⁶⁴	Conversion disorder in patients with chronic pain = 1/43 (2%)	Moderate (6)

FND = functional neurological disorder; FMD = functional movement disorder; FS = functional seizures; FNS = functional neurological symptoms; mFND = motor FND; FMS = functional movement symptoms; FD = functional dystonia; FW = functional weakness; FJ = functional jerks; FGD = functional gait disorder; FT = functional tremor; GP = general practitioner; NOS = Newcastle-Ottawa Scale (scored out of nine); SF-36 = 36-Item Short Form Survey; VAS = Visual Analogue Scale; PCS = Pain Catastrophising Scale; BPI = Brief Pain Inventory; PDI = Pain Disability Index; SD = standard deviation; IQR = interquartile range.

References

1. Delgado C, Kurtis M, Martin B, et al. Clinical and demographic characteristics of patients with functional movement disorders: a consecutive cohort study from a specialized clinic. *Acta Neurol Belg*. 2022;122(1):97-103. doi:10.1007/s13760-021-01648-8
2. Forejtová Z, Serranová T, Sieger T, et al. The complex syndrome of functional neurological disorder. *Psychol Med*. Published online January 7, 2022:1-11. doi:10.1017/S0033291721005225
3. Gandolfi M, Sandri A, Geroin C, et al. Improvement in motor symptoms, physical fatigue, and self-rated change perception in functional motor disorders: a prospective cohort study of a 12-week telemedicine program. *J Neurol*. 2022;269(11):5940-5953. doi:10.1007/s00415-022-11230-8
4. Geroin C, Stone J, Camozzi S, Demartini B, Gandolfi M, Tinazzi M. Triggers in functional motor disorder: a clinical feature distinct from precipitating factors. *J Neurol*. 2022;269(7):3892-3898. doi:10.1007/s00415-022-11102-1
5. Gorenflo R, Ho R, Carrazana E, et al. Identification of risk factors and distinguishing psychogenic nonepileptic seizures from epilepsy: A retrospective case-control study. *Clinical Neurology and Neurosurgery*. 2022;217:107221. doi:10.1016/j.clineuro.2022.107221
6. Massot-Tarrús A, Joe Yu Y, AlKhateeb M, Mirsattari SM. Factors associated with comorbid epilepsy in patients with psychogenic nonepileptic seizures: A large cohort study. *Epilepsy & Behavior*. 2022;134:108780. doi:10.1016/j.yebeh.2022.108780
7. Mostile G, Geroin C, Erro R, et al. Data-driven clustering of combined Functional Motor Disorders based on the Italian registry. *Front Neurol*. 2022;13:987593. doi:10.3389/fneur.2022.987593
8. Sandri A, Di Vico IA, Riello M, Marotta A, Tinazzi M. The impact of recurrent Covid-19 waves on patients with Functional Movement Disorders: A follow-up study. *Clinical Parkinsonism & Related Disorders*. 2022;6:100139. doi:10.1016/j.prdoa.2022.100139
9. Teodoro T, Koreki A, Chen J, et al. Functional cognitive disorder affects reaction time, subjective mental effort and global metacognition. *Brain*. Published online October 6, 2022:awac363. doi:10.1093/brain/awac363
10. Gandolfi M, Riello M, Bellamoli V, et al. Motor and non-motor outcomes after a rehabilitation program for patients with Functional Motor Disorders: A prospective, observational cohort study. *NRE*. 2021;48(3):305-314. doi:10.3233/NRE-201617
11. Gray J, Welck M, Cullen NP, Singh D. Functional dystonia in the foot and ankle. *The Bone & Joint Journal*. 2021;103-B(6):1127-1132. doi:10.1302/0301-620X.103B6.BJJ-2020-2187.R2
12. Katyal R, Paul A, Xu C, et al. Diagnostic Yield of 8-Hour Video-EEG in Detecting Psychogenic Non-Epileptic Seizures (PNES). *The Neurodiagnostic Journal*. 2021;61(4):186-195. doi:10.1080/21646821.2021.2001246
13. Lagrand T, Tuitert I, Klamer M, et al. Functional or not functional; that's the question: Can we predict the diagnosis functional movement disorder based on associated features? *Eur J Neurol*. 2021;28(1):33-39. doi:10.1111/ene.14488
14. Tinazzi M, Geroin C, Marcuzzo E, et al. Functional motor phenotypes: to lump or to split? *J Neurol*. 2021;268(12):4737-4743. doi:10.1007/s00415-021-10583-w
15. Stephen CD, Perez DL, Chibnik LB, Sharma N. Functional dystonia: A case-control study and risk prediction algorithm. *Ann Clin Transl Neurol*. 2021;8(4):732-748. doi:10.1002/acn3.51307
16. Aybek S, Lidstone SC, Nielsen G, et al. What Is the Role of a Specialist Assessment Clinic for FND? Lessons From Three National Referral Centers. *JNP*. 2020;32(1):79-84. doi:10.1176/appi.neuropsych.19040083
17. Gelauff JM, Rosmalen JGM, Gardien J, Stone J, Tijssen MAJ. Shared demographics and comorbidities in different functional motor disorders. *Parkinsonism & Related Disorders*. 2020;70:1-6. doi:10.1016/j.parkreldis.2019.11.018
18. Linden SC. Triggers and Clinical Presentations of Functional Neurological Disorders: Lessons from World War 1. *Eur Neurol*. 2020;83(2):174-181. doi:10.1159/000507698
19. O'Connell N, Watson G, Grey C, Pastena R, McKeown K, David AS. Outpatient CBT for Motor Functional Neurological Disorder and Other Neuropsychiatric Conditions: A Retrospective Case Comparison. *JNP*. 2020;32(1):58-66. doi:10.1176/appi.neuropsych.19030067

20. Stone J, Warlow C, Deary I, Sharpe M. Predisposing Risk Factors for Functional Limb Weakness: A Case-Control Study. *JNP*. 2020;32(1):50-57. doi:10.1176/appi.neuropsych.19050109
21. Tinazzi M, Morgante F, Marcuzzo E, et al. Clinical Correlates of Functional Motor Disorders: An Italian Multicenter Study. *Mov Disord Clin Pract*. 2020;7(8):920-929. doi:10.1002/mdc3.13077
22. Tomić A, Ječmenica Lukić M, Petrović I, et al. Changes of Phenotypic Pattern in Functional Movement Disorders: A Prospective Cohort Study. *Front Neurol*. 2020;11:582215. doi:10.3389/fneur.2020.582215
23. Van der Feltz-Cornelis CM, Allen SF, Van Eck van der Sluijs JF. Childhood sexual abuse predicts treatment outcome in conversion disorder/functional neurological disorder. An observational longitudinal study. *Brain Behav*. 2020;10(3). doi:10.1002/brb3.1558
24. Gelauff JM, Carson A, Ludwig L, Tijssen MAJ, Stone J. The prognosis of functional limb weakness: a 14-year case-control study. *Brain*. 2019;142(7):2137-2148. doi:10.1093/brain/awz138
25. Hanzlíková Z, Kofler M, Slovák M, et al. Prepulse inhibition of the blink reflex is abnormal in functional movement disorders. *Mov Disord*. 2019;34(7):1022-1030. doi:10.1002/mds.27706
26. Jennum P, Ibsen R, Kjellberg J. Morbidity and mortality of nonepileptic seizures (NES): A controlled national study. *Epilepsy & Behavior*. 2019;96:229-233. doi:10.1016/j.yebeh.2019.03.016
27. Jimenez XF, Aboussouan A, Johnson J. Functional Neurological Disorder Responds Favorably to Interdisciplinary Rehabilitation Models. *Psychosomatics*. 2019;60(6):556-562. doi:10.1016/j.psym.2019.07.002
28. Serranová T, Slovák M, Kemlink D, Šonka K, Hallett M, Růžička E. Prevalence of restless legs syndrome in functional movement disorders: a case-control study from the Czech Republic. *BMJ Open*. 2019;9(1):e024236. doi:10.1136/bmjopen-2018-024236
29. Gelauff JM, Kingma EM, Kalkman JS, et al. Fatigue, not self-rated motor symptom severity, affects quality of life in functional motor disorders. *J Neurol*. 2018;265(8):1803-1809. doi:10.1007/s00415-018-8915-7
30. Glass SP, Matin N, Williams B, et al. Neuropsychiatric Factors Linked to Adherence and Short-Term Outcome in a U.S. Functional Neurological Disorders Clinic: A Retrospective Cohort Study. *JNP*. 2018;30(2):152-159. doi:10.1176/appi.neuropsych.17060117
31. Morgante F, Matinella A, Andrenelli E, et al. Pain processing in functional and idiopathic dystonia: An exploratory study: Pain Processing in CD and F-Dys. *Mov Disord*. 2018;33(8):1340-1348. doi:10.1002/mds.27402
32. Petrović IN, Tomić A, Vončina MM, Pešić D, Kostić VS. Characteristics of two distinct clinical phenotypes of functional (psychogenic) dystonia: follow-up study. *J Neurol*. 2018;265(1):82-88. doi:10.1007/s00415-017-8667-9
33. Věchetová G, Slovák M, Kemlink D, et al. The impact of non-motor symptoms on the health-related quality of life in patients with functional movement disorders. *Journal of Psychosomatic Research*. 2018;115:32-37. doi:10.1016/j.jpsychores.2018.10.001
34. Erba G, Bianchi E, Giussani G, Langfitt J, Juersivich A, Beghi E. Patients' and caregivers' contributions for differentiating epileptic from psychogenic nonepileptic seizures. Value and limitations of self-reporting questionnaires: A pilot study. *Seizure*. 2017;53:66-71. doi:10.1016/j.seizure.2017.11.001
35. Kerr WT, Janio EA, Braesch CT, et al. Identifying psychogenic seizures through comorbidities and medication history. *Epilepsia*. 2017;58(11):1852-1860. doi:10.1111/epi.13888
36. Matin N, Young SS, Williams B, et al. Neuropsychiatric Associations With Gender, Illness Duration, Work Disability, and Motor Subtype in a U.S. Functional Neurological Disorders Clinic Population. *JNP*. 2017;29(4):375-382. doi:10.1176/appi.neuropsych.16110302
37. Nielsen G, Buszewicz M, Stevenson F, et al. Randomised feasibility study of physiotherapy for patients with functional motor symptoms. *J Neurol Neurosurg Psychiatry*. 2017;88(6):484-490. doi:10.1136/jnnp-2016-314408
38. Pleizier M, de Haan RJ, Vermeulen M. Management of patients with functional neurological symptoms: a single-centre randomised controlled trial. *J Neurol Neurosurg Psychiatry*. 2017;88(5):430-436. doi:10.1136/jnnp-2015-312889

39. Zutt R, Gelauff JM, Smit M, van Zijl JC, Stone J, Tijssen MAJ. The presence of depression and anxiety do not distinguish between functional jerks and cortical myoclonus. *Parkinsonism & Related Disorders*. 2017;45:90-93. doi:10.1016/j.parkreldis.2017.09.023
40. Perez DL, Young SS, King JN, et al. Preliminary Predictors of Initial Attendance, Symptom Burden, and Motor Subtype in a US Functional Neurological Disorders Clinic Population. *Cognitive and Behavioral Neurology*. 2016;29(4):197-205. doi:10.1097/WNN.000000000000106
41. Salinsky M, Storzbach D, Goy E, Kellogg M, Boudreau E. Health care utilization following diagnosis of psychogenic nonepileptic seizures. *Epilepsy & Behavior*. 2016;60:107-111. doi:10.1016/j.yebeh.2016.04.007
42. Elliott JO, Charyton C. Biopsychosocial predictors of psychogenic non-epileptic seizures. *Epilepsy Research*. 2014;108(9):1543-1553. doi:10.1016/j.eplepsyres.2014.09.003
43. Pareés I, Kojovic M, Pires C, et al. Physical precipitating factors in functional movement disorders. *Journal of the Neurological Sciences*. 2014;338(1-2):174-177. doi:10.1016/j.jns.2013.12.046
44. Thomas AA, Preston J, Scott RC, Bujarski KA. Diagnosis of probable psychogenic nonepileptic seizures in the outpatient clinic: Does gender matter? *Epilepsy & Behavior*. 2013;29(2):295-297. doi:10.1016/j.yebeh.2013.08.006
45. Gazzola DM, Carlson C, Rugino A, Hirsch S, Starner K, Devinsky O. Psychogenic nonepileptic seizures and chronic pain: A retrospective case-controlled study. *Epilepsy & Behavior*. 2012;25(4):662-665. doi:10.1016/j.yebeh.2012.10.008
46. Driver-Dunckley E, Stonnington CM, Locke DEC, Noe K. Comparison of Psychogenic Movement Disorders and Psychogenic Nonepileptic Seizures: Is Phenotype Clinically Important? *Psychosomatics*. 2011;52(4):337-345. doi:10.1016/j.psym.2011.01.008
47. Stone J, Warlow C, Sharpe M. The symptom of functional weakness: a controlled study of 107 patients. *Brain*. 2010;133(5):1537-1551. doi:10.1093/brain/awq068
48. Ibrahim NM, Martino D, van de Warrenburg BPC, et al. The prognosis of fixed dystonia: A follow-up study. *Parkinsonism & Related Disorders*. 2009;15(8):592-597. doi:10.1016/j.parkreldis.2009.02.010
49. Kuyk J, Siffels MC, Bakvis P, Swinkels WAM. Psychological treatment of patients with psychogenic non-epileptic seizures: An outcome study. *Seizure*. 2008;17(7):595-603. doi:10.1016/j.seizure.2008.02.006
50. Hantke NC, Doherty MJ, Haltiner AM. Medication use profiles in patients with psychogenic nonepileptic seizures. *Epilepsy & Behavior*. 2007;10(2):333-335. doi:10.1016/j.yebeh.2006.11.014
51. Reuber M, Burness C, Howlett S, Brazier J, Grünewald R. Tailored psychotherapy for patients with functional neurological symptoms: A pilot study. *Journal of Psychosomatic Research*. 2007;63(6):625-632. doi:10.1016/j.jpsychores.2007.06.013
52. Dworetzky BA, Strahonja-Packard A, Shanahan CW, Paz J, Schauble B, Bromfield EB. Characteristics of Male Veterans with Psychogenic Nonepileptic Seizures. *Epilepsia*. 2005;46(9):1418-1422. doi:10.1111/j.1528-1167.2005.13004.x
53. Schrag A, Trimble M, Quinn N, Bhatia K. The syndrome of fixed dystonia: an evaluation of 103 patients. *Brain*. 2004;127(10):2360-2372. doi:10.1093/brain/awh262
54. Stone J, Sharpe M, Binzer M. Motor Conversion Symptoms and Pseudoseizures: A Comparison of Clinical Characteristics. *Psychosomatics*. 2004;45(6):492-499. doi:10.1176/appi.psy.45.6.492
55. Fishbain DA, Cutler RB, Lewis J, Cole B, Rosomoff RS, Rosomoff HL. Is the Location of Nondermatomal Sensory Abnormalities (NDSAs) Related to Pain Location? *Pain Med*. 2003;4(3):238-243. doi:10.1046/j.1526-4637.2003.03029.x
56. Birket-Smith M, Mortensen EL. Pain in somatoform disorders: is somatoform pain disorder a valid diagnosis?: Pain in somatoform disorders. *Acta Psychiatrica Scandinavica*. 2002;106(2):103-108. doi:10.1034/j.1600-0447.2002.02219.x
57. Ettinger AB, Devinsky O, Weisbrot DM, Goyal A, Shashikumar S. Headaches and other pain symptoms among patients with psychogenic non-epileptic seizures. *Seizure*. 1999;8(7):424-426. doi:10.1053/seiz.1999.0334

58. Barry E, Krumholz A, Bergey GK, Chatha H, Alemayehu S, Grattan L. Nonepileptic Posttraumatic Seizures. *Epilepsia*. 1998;39(4):427-431. doi:10.1111/j.1528-1157.1998.tb01395.x
59. Dula DJ, DeNaples L. Emergency Department Presentation of Patients with Conversion Disorder. *Academic Emergency Medicine*. 1995;2(2):120-123. doi:10.1111/j.1553-2712.1995.tb03174.x
60. Fishbain DA, Goldberg M, Rosomoff RS, Rosomoff H. Chronic Pain Patients and the Nonorganic Physical Sign of Nondermatomal Sensory Abnormalities (NDSA). *Psychosomatics*. 1991;32(3):294-303. doi:10.1016/S0033-3182(91)72068-9
61. Lempert T, Schmidt D. Natural history and outcome of psychogenic seizures: a clinical study in 50 patients. *J Neurol*. 1990;237(1):35-38. doi:10.1007/BF00319665
62. Weintraub MI. Regional Pain Is Usually Hysterical. *Archives of Neurology*. 1988;45(8):914-915. doi:10.1001/archneur.1988.00520320116025
63. Fishbain DA, Goldberg M, Meagher RB, Steele R, Rosomoff H. Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria. *Pain*. 1986;26(2):181-197. doi:10.1016/0304-3959(86)90074-6
64. Reich J, Tupin J, Abramowitz S. Psychiatric diagnosis of chronic pain patients. *AJP*. 1983;140(11):1495-1498. doi:10.1176/ajp.140.11.1495